BHVN$10.24-9.3%MYGN$4.22+7.4%CLPT$12.24+6.4%AGIO$30.42+6.3%MRVI$4.64+6.2%CRSP$56.38+5.3%VERA$35.86+4.6%LLY$1126.80+4.1%EDIT$3.43-3.9%SRPT$17.30+3.7%RLAY$13.90-3.7%DNLI$20.95+3.7%BHVN$10.24-9.3%MYGN$4.22+7.4%CLPT$12.24+6.4%AGIO$30.42+6.3%MRVI$4.64+6.2%CRSP$56.38+5.3%VERA$35.86+4.6%LLY$1126.80+4.1%EDIT$3.43-3.9%SRPT$17.30+3.7%RLAY$13.90-3.7%DNLI$20.95+3.7%
Alpha pilot · Q2 2026

Cut through the biotech noise.

Lucent Intel turns 100K+ daily signals from analysts, FDA filings, and earnings calls into actionable intelligence for biopharma traders. One chat tab. Source-cited answers.

Have an invite code? Request access →
39 tickers tracked·10 news sources·last refresh 3h ago

Signal of the day

extracted 17h ago
$REPLSignal score0.8
How many times can you play the pre-PDUFA ramp-up with $REPL? https://t.co/MWuIbX0e2H

@Investorclimber · Investor & Climber · 17h ago

1 ticker cited6 likes0 reposts
Open in chat →

Latest intelligence

View feed →
PubMed·Dec 31
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMed·Dec 31
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).
PubMed·Dec 20
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.

Research evaluates the safety and efficacy of allogeneic CD19 CAR NK-cell therapy for SLE, suggesting a potential safety alternative to autologous CAR T cells, but does not identify a specific company for investors.

·11h ago

$REPL REPLIMUNE TO RESUBMIT ITS TWICE-REJECTED CANCER DRUG APPLICATION AFTER RECENT FDA LEADERSHIP CHANGES, FOLLOWING COMPLAINTS ABOUT INCONSISTENT TRIAL AND APPROVAL GUIDANCE.

@MultibaggAIHQ · 0.7 signal score$REPL
·15h ago

$REPL Replimune gives cancer immunotherapy a third try after FDA leadership shakeup - Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in pla...

@MarcJacksonLA · 0.7 signal score$REPL

What's inside the platform

Four primitives. Every catalyst in biopharma.

Signal extraction

Every analyst post, FDA filing, and earnings call parsed and scored in minutes.

Catalyst calendar

1,200+ tracked events: PDUFAs, AdComs, readouts, earnings, conferences.

Cross-trial efficacy

Normalized endpoints across competing programs. Compare apples to apples.

Read-through alerts

Watch one ticker. Get alerted when something hits a related substance or peer.

Pilot launching this quarter

We're inviting a small group of biopharma traders to the alpha. Tell us about your workflow and we'll be in touch.

39 tickers tracked
2 events next 7 days
6 posts today
10 news sources
last pipeline run 3h ago